Maxcyte (MXCT) Long-Term Deferred Tax (2019 - 2025)
Maxcyte (MXCT) reported Long-Term Deferred Tax of $945000.0 for Q4 2025, down 38.11% year-over-year from $1.5 million in Q4 2024, and down 38.11% quarter-over-quarter from $1.5 million in Q4 2024.
Maxcyte (MXCT) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends
Maxcyte (MXCT) has 3 years of Long-Term Deferred Tax data on file, last reported at $945000.0 in Q4 2025.
- Long-Term Deferred Tax for Q4 2025 came in at $945000.0, down 38.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $945000.0 (down 38.11% YoY), and the FY2025 annual result was $945000.0, down 38.11% from the prior year.
- Long-Term Deferred Tax slipped to $945000.0 in Q4 2025 per MXCT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $1.5 million in Q4 2024 and troughed at $945000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Maxcyte | 127.72 Mn | 127.72 Mn | 8.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 945,000.00 |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2019 | 965,800.00 |